Cardiac complications of halofantrine: a prospective study of 20 patients

Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):430-3. doi: 10.1016/0035-9203(95)90041-1.

Abstract

Halofantrine, increasingly used for treatment of Plasmodium falciparum malaria, is a normally well-tolerated amino-alcohol with very few side-effects, but torsades de pointes ventricular tachycardia due to halofantrine has been reported in a few patients with a congenital long QT interval (Romano-Ward syndrome). We performed a prospective study of the cardiac effect of halofantrine in 20 patients with 48 h ambulatory electrocardiographic (ECG) monitoring; the halofantrine levels in their serum were also determined. Minimal ECG changes were noted, with lengthening of the QT interval without clinical symptoms. This effect was dose-dependent and can be very severe in cases of pre-existing cardiopathy; it also occurs in patients without any pre-existing cardiopathy. In order to reduce the likelihood of such incidents, which are admittedly rare, we suggest performing electrocardiography on all patients before initiating treatment with halofantrine.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimalarials / adverse effects*
  • Antimalarials / blood
  • Electrocardiography, Ambulatory / drug effects
  • Female
  • Humans
  • Malaria, Falciparum / blood
  • Malaria, Falciparum / drug therapy*
  • Malaria, Vivax / blood
  • Malaria, Vivax / drug therapy*
  • Male
  • Middle Aged
  • Phenanthrenes / adverse effects*
  • Phenanthrenes / blood
  • Prospective Studies

Substances

  • Antimalarials
  • Phenanthrenes
  • halofantrine